Bogdan Badic1,2, Maude Oguer3, Melanie Cariou4,5, Tiphaine Kermarrec4,5, Servane Bouzeloc4,5, Jean-Baptiste Nousbaum4,5,6, Michel Robaszkiewicz4,5,6, Lucille Queneherve4,5,6. 1. CHRU Brest, Service de Chirurgie Viscérale, Brest, France. bogdan.badic@chu-brest.fr. 2. INSERM, UMR 1101, LaTIM, 22 rue Camille Desmoulins, 29238, Brest, France. bogdan.badic@chu-brest.fr. 3. CHRU Brest, Service de Chirurgie Viscérale, Brest, France. 4. Registre des Cancers Digestifs du Finistère, Brest, France. 5. EA7479 SPURBO, Université de Bretagne Occidentale, Brest, France. 6. CHRU Brest, Service d'Hépato-gastro-entérologie, Brest, France.
Abstract
PURPOSE: Oncological strategies in the elderly population are debated. The objective of this study was to assess the factors predictive of poor prognosis in elderly patients with stage III colon cancer. METHODS: A retrospective review of demographic, pathologic, treatment, and outcome data from 308 patients with stage III colon adenocarcinoma who had undergone surgery between 2007 and 2014 was conducted. A proportional hazards model was used to assess the association of prognostic factors with disease-free survival (DFS) and overall survival (OS). RESULTS: The 5-year survival rate was 34.4% (95% CI 27.1-39.8%) and Charlson comorbidity index was a significant predictor of death (p < 0.01). The presence of perineural invasion (p = 0.03) and incomplete resection (p < 0.001) were significantly correlated with OS. The postoperative (30 days) mortality rate was 11.7%. Adjuvant chemotherapy was significantly associated with better OS (p < 0.001) independently of the regimens. Disease-free survival was significantly correlated with adjuvant chemotherapy (HR 0.63, 95% CI: 0.42-0.97, p = 0.034), Charlson comorbidity index (CCI 5; HR 1.61, 95% CI: 1.05-2.48, p = 0.029), and venous and/or perineural invasion (HR 1.54, 95% CI: 1.03-2.29, p = 0.035). CONCLUSION: Age, comorbidities, tumor histology, and adjuvant chemotherapy were independent predictors of prognosis in patients with stage III colon cancer. These data can be used to identify elderly patients with poor prognosis and to design future tailored randomized clinical trials. TRIAL REGISTRATION: ClinicalTrial.gov No. NCT04526314. Date of registration 25 August 2020.
PURPOSE: Oncological strategies in the elderly population are debated. The objective of this study was to assess the factors predictive of poor prognosis in elderly patients with stage III colon cancer. METHODS: A retrospective review of demographic, pathologic, treatment, and outcome data from 308 patients with stage III colon adenocarcinoma who had undergone surgery between 2007 and 2014 was conducted. A proportional hazards model was used to assess the association of prognostic factors with disease-free survival (DFS) and overall survival (OS). RESULTS: The 5-year survival rate was 34.4% (95% CI 27.1-39.8%) and Charlson comorbidity index was a significant predictor of death (p < 0.01). The presence of perineural invasion (p = 0.03) and incomplete resection (p < 0.001) were significantly correlated with OS. The postoperative (30 days) mortality rate was 11.7%. Adjuvant chemotherapy was significantly associated with better OS (p < 0.001) independently of the regimens. Disease-free survival was significantly correlated with adjuvant chemotherapy (HR 0.63, 95% CI: 0.42-0.97, p = 0.034), Charlson comorbidity index (CCI 5; HR 1.61, 95% CI: 1.05-2.48, p = 0.029), and venous and/or perineural invasion (HR 1.54, 95% CI: 1.03-2.29, p = 0.035). CONCLUSION:Age, comorbidities, tumor histology, and adjuvant chemotherapy were independent predictors of prognosis in patients with stage III colon cancer. These data can be used to identify elderly patients with poor prognosis and to design future tailored randomized clinical trials. TRIAL REGISTRATION: ClinicalTrial.gov No. NCT04526314. Date of registration 25 August 2020.
Entities:
Keywords:
Chemotherapy; Elderly; Stage III colon cancer; Surgery; Survival
Authors: Basilio Pirrera; Samuele Vaccari; Dajana Cuicchi; Ferdinando Lecce; Emilio De Raffele; Barbara Dalla Via; Marco Di Laudo; Valeria Tonini; Maurizio Cervellera; Bruno Cola Journal: Int J Surg Date: 2016-09-09 Impact factor: 6.071
Authors: J W T Dekker; C B M van den Broek; E Bastiaannet; L G M van de Geest; R A E M Tollenaar; G J Liefers Journal: Ann Surg Oncol Date: 2011-03-29 Impact factor: 5.344
Authors: P Connor Johnson; Alisha Yi; Nora Horick; Hermioni L Amonoo; Richard A Newcomb; Mitchell W Lavoie; Julia Rice; Matthew J Reynolds; Christine S Ritchie; Ryan D Nipp; Areej El-Jawahri Journal: Oncologist Date: 2021-08-12 Impact factor: 5.837